Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Universitaet Leipzig

Leipzig, GermanyLeipzig University

192running trials
63closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· Phase 3· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Source
Not yet recruiting
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· Phase 3· Source
Recruiting
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574· Phase 2· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· Source
Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163· Phase 2· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Source
Recruiting
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· Phase 3· Source
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· Phase 3· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· Phase 3· Source
Recruiting
Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.
NCT07843927· Phase 3· Source
Recruiting
PREFer
NCT06916416· Phase 2· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
2025-524014-29-00· Phase 3· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· Phase 3· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218· Phase 3· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Source
Recruiting
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· Phase 3· Source
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Source
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· Phase 3· Source
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06875128· Phase 2· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Source
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· Phase 3· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· Source
Recruiting
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
2024-512503-39-00· Phase 4· Source
Active, not recruiting
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038)
2025-521970-33-00· Phase 3· Source
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585· Phase 3· Source
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Source
Recruiting
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
NCT06804161· Phase 3· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Source
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· Phase 3· Source
Recruiting
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
2025-523061-22-00· Phase 2· Source
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Source
Recruiting
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
NCT05293080· Phase 3· Source
Recruiting
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
Essentiale® liquid once-daily Phase III study
2025-521678-32-00· Phase 3· Source
Active, not recruiting
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
2024-517818-15-00· Phase 1/2· Source
Completed
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP
2024-518364-12-00· Phase 2· Source
Active, not recruiting
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884· Phase 2· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· Source
Active, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· Phase 2· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Source
Completed
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis”
2023-503289-22-00· Phase 2· Source
Completed
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671· Phase 1· Source
Active, not recruiting
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167· Phase 2/3· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Source
Completed
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis
NCT05984784· Phase 1/2· Source
Completed
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).
NCT05975905· Phase 2· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2023-509472-42-00· Phase 3· Source
Completed
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax
2023-505828-58-00· Phase 1· Source
Completed
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· Phase 1/2· Source
Completed
A Study to Investigate MBS2320 Patients with IPF
2023-504418-30-00· Phase 2· Source
Active, not recruiting
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE
2022-502105-15-00· Phase 2· Source
Completed
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· Phase 2· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· Phase 2· Source
Completed
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
NCT05882734· Phase 1/2· Source
Completed
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· Phase 2· Source
Completed
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.
2024-512646-42-00· Phase 2· Source
Completed
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021· Phase 3· Source
Completed
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843· Phase 1/2· Source
Active, not recruiting
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066· Phase 2· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Source
Completed
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)
2023-508528-36-00· Phase 3· Source
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Source
Completed
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)
NCT05111626· Phase 3· Source
Completed
A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.
NCT04811092· Phase 3· Source
Completed
Tiotropium in preventing preschool asthma (TIPP)
2024-513916-84-00· Phase 3· Source
Active, not recruiting
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
NCT05104866· Phase 3· Source
Active, not recruiting
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385· Phase 1/2· Source
Completed
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease.
NCT04798430· Phase 3· Source
Completed
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
2024-512717-41-00· Phase 2· Source
Completed
A Long-term Follow-up Study of Sotatercept for PAH Treatment
NCT04796337· Phase 3· Source
Completed
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
NCT04526899· Phase 2· Source
Completed
RegoNivo vs Standard of Care Chemotherapy in AGOC
NCT04879368· Phase 3· Source
Active, not recruiting
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378· Phase 2· Source
Active, not recruiting
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991· Phase 3· Source
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· Phase 3· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· Phase 3· Source
Active, not recruiting
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963· Phase 3· Source
Completed
Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)
NCT04161885· Phase 3· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – Universitaet Leipzig: trial site – Frontlight Research